论文部分内容阅读
目的:评价头孢哌酮-舒巴坦用于治疗老年心力衰竭患者伴肺部感染的临床疗效。方法:选取2013年1月—2015年1月期间诊治的老年心力衰竭伴肺部感染患者113例,采用随机数字表法将其分为对照组56例和观察组57例;对照组患者均给予头孢曲松钠治疗,观察组患者均给予头孢哌酮-舒巴坦治疗,比较两组患者治疗后的总有效率和体温恢复正常时间、咳嗽消失时间和住院时间。结果:观察组患者治疗后的总有效率为98.25%高于对照组为80.36%(P<0.05),体温恢复时间、咳嗽消失时间和住院时间均明显短于对照组(P<0.05)。结论:采用头孢哌酮-舒巴坦治疗老年心力衰竭患者伴肺部感染的临床疗效优于头孢曲松钠。
Objective: To evaluate the clinical efficacy of cefoperazone-sulbactam in the treatment of elderly patients with heart failure and pulmonary infection. Methods: A total of 113 elderly patients with heart failure and pulmonary infection diagnosed and treated between January 2013 and January 2015 were selected and divided into control group (56 cases) and observation group (57 cases) by random number table Ceftriaxone sodium treatment, the observation group were given cefoperazone - sulbactam treatment, the two groups were compared after treatment, the total effective rate and body temperature recovery time, cough disappear time and hospital stay. Results: The total effective rate after treatment in the observation group was 98.25% higher than that in the control group (80.36%, P <0.05). The body temperature recovery time, cough disappearance time and hospitalization time were significantly shorter than those in the control group (P <0.05). Conclusion: Cefoperazone-sulbactam is superior to ceftriaxone in the treatment of senile heart failure patients with pulmonary infection.